These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 10221686)
21. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Out HJ; Rutherford A; Fleming R; Tay CC; Trew G; Ledger W; Cahill D Hum Reprod; 2004 Jan; 19(1):90-5. PubMed ID: 14688163 [TBL] [Abstract][Full Text] [Related]
22. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Devroey P; Fauser BC; Platteau P; Beckers NG; Dhont M; Mannaerts BM J Clin Endocrinol Metab; 2004 May; 89(5):2062-70. PubMed ID: 15126522 [TBL] [Abstract][Full Text] [Related]
23. Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta. Harlin J; Csemiczky G; Wramsby H; Fried G Hum Reprod; 2000 Feb; 15(2):239-44. PubMed ID: 10655291 [TBL] [Abstract][Full Text] [Related]
24. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477 [TBL] [Abstract][Full Text] [Related]
25. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation]. Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561 [TBL] [Abstract][Full Text] [Related]
26. A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization. Thuesen LL; Loft A; Egeberg AN; Smitz J; Petersen JH; Andersen AN Hum Reprod; 2012 Oct; 27(10):3074-84. PubMed ID: 22791754 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial. Hedon B; Out HJ; Hugues JN; Camier B; Cohen J; Lopes P; Zorn JR; van der Heijden B; Coelingh Bennink HJ Hum Reprod; 1995 Dec; 10(12):3102-6. PubMed ID: 8822422 [TBL] [Abstract][Full Text] [Related]
28. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. Hohmann FP; Macklon NS; Fauser BC J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847 [TBL] [Abstract][Full Text] [Related]
29. The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety. Ashrafi M; Kiani K; Ghasemi A; Rastegar F; Nabavi M Arch Gynecol Obstet; 2011 Dec; 284(6):1431-8. PubMed ID: 21210134 [TBL] [Abstract][Full Text] [Related]
30. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women. Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425 [TBL] [Abstract][Full Text] [Related]
31. Outcome from consecutive in-vitro fertilization/intracytoplasmic sperm injection attempts in the final group treated with urinary gonadotrophins and the first group treated with recombinant follicle stimulating hormone. Jacob S; Drudy L; Conroy R; Harrison RF Hum Reprod; 1998 Jul; 13(7):1783-7. PubMed ID: 9740423 [TBL] [Abstract][Full Text] [Related]
32. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Vuong TN; Phung HT; Ho MT Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882 [TBL] [Abstract][Full Text] [Related]
33. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Lefebvre J; Antaki R; Kadoch IJ; Dean NL; Sylvestre C; Bissonnette F; Benoit J; Ménard S; Lapensée L Fertil Steril; 2015 Dec; 104(6):1419-25. PubMed ID: 26361207 [TBL] [Abstract][Full Text] [Related]
35. A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients. Jansen CA; van Os HC; Out HJ; Coelingh Bennink HJ Hum Reprod; 1998 Nov; 13(11):2995-9. PubMed ID: 9853844 [TBL] [Abstract][Full Text] [Related]
36. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. Daya S; Gunby J Cochrane Database Syst Rev; 2000; (4):CD002810. PubMed ID: 11034767 [TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Tan SL; Child TJ; Cheung AP; Fluker MR; Yuzpe A; Casper R; Leung P; Cadesky K; Davis VJ J Assist Reprod Genet; 2005 Feb; 22(2):81-8. PubMed ID: 15844733 [TBL] [Abstract][Full Text] [Related]
38. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. Calaf Alsina J; Ruiz Balda JA; Romeu Sarrió A; Caballero Fernández V; Cano Trigo I; Gómez Parga JL; González Batres C; Rodríguez Escudero FJ BJOG; 2003 Dec; 110(12):1072-7. PubMed ID: 14664878 [TBL] [Abstract][Full Text] [Related]
39. Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon). Buckler HM; Robertson WR; Anderson A; Vickers M; Lambert A Hum Reprod; 1999 Dec; 14(12):2969-73. PubMed ID: 10601080 [TBL] [Abstract][Full Text] [Related]
40. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial. Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]